BACKGROUND: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, trauma patient to have an improved outcome during rehabilitation therapy. METHODS:Patients with major blunt trauma orthopedic injuries were administered epoetin alfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. RESULTS:One hundred ninety-two patients were enrolled (epoetin alfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetin alfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetin alfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. CONCLUSIONS: No differences were observed in physical function outcomes or safety in anemic, critically ill, trauma patients treated with epoetin alfa compared with placebo.
RCT Entities:
BACKGROUND: Achieving a higher hemoglobin (Hb) level might allow the anemic, critically ill, traumapatient to have an improved outcome during rehabilitation therapy. METHODS:Patients with major blunt trauma orthopedic injuries were administered epoetinalfa or placebo weekly both in hospital and for up to 12 weeks after discharge or until the Hb level was >12.0 g/dL, whichever occurred first. The 36-question Short Form Health Assessment questionnaire (SF-36) was used to evaluate physical function (PF) outcomes at baseline, at hospital discharge, and at several time points posthospital discharge. RESULTS: One hundred ninety-two patients were enrolled (epoetinalfa [n = 97], placebo [n = 95]). Hb increased from baseline to hospital discharge in both groups (epoetinalfa: 1.2 g/dL vs placebo: 0.9 g/dL), and transfusion requirements were similar between groups. Both groups showed improvements in SF-36 PF; there were no significant differences in the average of all posthospital discharge scores (epoetinalfa: 27.3 vs placebo 30.9; P = 0.38). Thromboembolic events were similar between groups. CONCLUSIONS: No differences were observed in physical function outcomes or safety in anemic, critically ill, traumapatients treated with epoetinalfa compared with placebo.
Authors: Ines G Alamo; Kolenkode B Kannan; Letitia E Bible; Tyler J Loftus; Harry Ramos; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2017-04 Impact factor: 3.313
Authors: Bita Mesgarpour; Benedikt H Heidinger; Michael Schwameis; Calvin Kienbacher; Cathal Walsh; Susanne Schmitz; Harald Herkner Journal: Intensive Care Med Date: 2013-08-09 Impact factor: 17.440
Authors: Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn Journal: Crit Care Date: 2016-04-12 Impact factor: 9.097
Authors: Oscar McCook; Michael Georgieff; Angelika Scheuerle; Peter Möller; Christoph Thiemermann; Peter Radermacher Journal: Crit Care Date: 2012-09-26 Impact factor: 9.097
Authors: Alexander P Vlaar; Simon Oczkowski; Sanne de Bruin; Marije Wijnberge; Massimo Antonelli; Cecile Aubron; Philippe Aries; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella Muller; Akshay Shah; Anders Perner; Sofie Rygaard; Timothy S Walsh; Gordon Guyatt; J C Dionne; Maurizio Cecconi Journal: Intensive Care Med Date: 2020-01-07 Impact factor: 17.440
Authors: A M Lynch; M Respess; A E Boll; M Bozych; M McMichael; D J Fletcher; A M De Laforcade; E A Rozanski Journal: J Vet Intern Med Date: 2015-11-17 Impact factor: 3.333